Cumberland Pharmaceuticals Inc. filed a Form 8-K with the SEC on October 26, 2026, disclosing plans to submit a New Drug Application to the FDA for ifetroban as a treatment for the cardiomyopathy associated with Duchenne muscular dystrophy, following a pre-NDA meeting held with the FDA in fall 2026.

Key Highlights

  • NDA planned: Cumberland's Board of Directors recently approved proceeding with a Traditional Approval NDA submission for ifetroban for DMD-related cardiomyopathy.
  • Phase 2 FIGHT DMD trial result: High-dose ifetroban produced a statistically significant 5.4% absolute improvement in left ventricular ejection fraction (LVEF) (p=0.002) compared to a combined control group.
  • Rolling review granted: The FDA granted the company's request for rolling review of the NDA, allowing completed sections to be submitted before the full application is filed.
  • Safety database: The planned NDA submission will include data from a safety database covering more than 1,400 subjects across approximately 30 clinical studies of ifetroban.
  • FDA designations: Ifetroban has received Orphan Drug Designation, Rare Pediatric Disease Designation, and Fast Track Designation from the FDA for cardiomyopathy associated with DMD.
  • Proprietary name accepted: The FDA has conditionally accepted DYSCORBAN as the proprietary name for the product.
  • FDA concerns noted: According to the filing, "FDA expressed concerns about whether the proposed data package would be sufficient to address the requirement for substantial evidence of efficacy needed for approval."

Cumberland Pharmaceuticals Advances Ifetroban NDA Amid FDA Questions on Efficacy Data

According to the filing, Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) disclosed on October 26, 2026, that it plans to submit an NDA to the U.S. Food and Drug Administration for ifetroban as a treatment for cardiomyopathy associated with Duchenne muscular dystrophy. The company described the decision as following a pre-NDA meeting held with the FDA in fall 2026, at which "the format and content of the planned submission were discussed including the needed reports and requested analysis."

The planned submission, the filing stated, will include data from the 12-month Phase 2 FIGHT DMD trial (NCT03340675) and its ongoing open-label extension, data from two natural history databases of DMD patients, preclinical data published in the Journal of the American Heart Association, manufacturing information, and the company's safety database. The FIGHT DMD trial demonstrated a statistically significant 5.4% absolute improvement in LVEF (p=0.002) in the high-dose ifetroban group compared to a control group composed of placebo-treated patients combined with propensity score-matched natural history patients. Study findings also included reductions in cardiac damage markers NT-proBNP and cardiac troponin I in the high-dose group. The filing noted that long-term cardiac MRI data from Months 24 and 36 of the open-label extension are being analyzed and will be included in the NDA.

The filing also disclosed that the company's path to submission followed an End-of-Phase 2 meeting with the FDA in September 2025 and a follow-up Type C meeting in January 2026, at which the FDA suggested a Phase 3, randomized, placebo-controlled trial and raised questions about the LVEF endpoint, comparator issues, and the statistical analysis plan. The filing included a caution that "there can be no assurance that the FDA will accept the NDA for filing or approve ifetroban on the basis of the data submitted, even with the inclusion of the additional analysis and information that FDA requested in the pre-NDA meeting." The filing further noted that exploratory biomarker analyses showed a 30% reduction in MYL3 and a 50% reduction in MYOD1, a 2.4-fold increase in FGF16, and a 2.1-fold increase in TSPAN7 with 12 months of high-dose treatment compared to the combined control group.

What Was Disclosed

Cumberland Pharmaceuticals filed an 8-K on October 26, 2026, disclosing its intention to submit an NDA for ifetroban for DMD cardiomyopathy, summarizing clinical trial results, FDA interactions, rolling review approval, and the FDA's expressed concerns about the sufficiency of the proposed data package.